UTv Videos

“One thing from our study that you can take home [is] no matter what the surgery is, small changes right after surgery can actually tell you more than we usually give them credit for,” says Sevag Demirjian, MD.

“The take home message would be that in patients with prior history of kidney stone episodes…receiving 24-hour urine testing prior to starting pharmacologic preventive therapy is associated with a lower probability of a subsequent stone-related event,” says Ryan Hsi, MD, FACS.

“[The prediction model] worked way better than we expected that it would work,” says Sevag Demirjian, MD.

“Botox has been a wonderful drug for many, many years,” says Min Dong, MD.

“I think the take home message is that [IsoPSA is] an easy test to use,” says Eric A. Klein, MD.

“I view OAB as a problem for many women that hasn't gotten the attention that it's needed over the decades,” says Alexandra Rogers, MD.

Abstracts highlight topics such as sacral neuromodulation and percutaneous tibial nerve stimulation.

The device is indicated for overactive bladder, chronic fecal incontinence, and non-obstructive urinary retention.

“The proportion of clinics that employ an onsite urologist, where the urologist is integrated into the flow of that clinic, is relatively small,” says Akanksha Mehta, MD, MS.

“I think that we keep getting better and better tools…[and] I think understanding how to utilize these tools will be a challenge in the future,” says David M. Schuster, MD, FACR.

“The idea is to develop strategies that reduce the likelihood of needing a biopsy or improving the sensitivity of the biopsy to find a high-grade cancer, one that's treatable,” says Eric A. Klein, MD.

“Patients are interested in exercise, they're really keen, they want to know what they can do to help themselves,” says Kerry S. Courneya, PhD.

“We found in this study that the exercise group had lower prostate cancer-specific anxiety compared to the group that didn't exercise,” says Kerry Courneya, PhD.

“IsoPSA is a way of measuring all the different PSA-related proteins in the blood,” says Eric A. Klein, MD.

“The prevalence of incontinence is high and increasing. We recommend routine screening for all women for this condition as a part of preventive health care,” says Ushma J. Patel, MD.

“Women often are afraid to ask for what they want because they don't want to be perceived as too aggressive or too bossy,” says Kate H. Kraft, MD.

“IsoPSA is intended to be used in men over 50 who are being screened for prostate cancer as a way of helping to decide whether or not a biopsy should be done,” says Eric A. Klein, MD.

In this video, Ryan J. Nelson, DO, and Steven Ogilvy, PA-C, demonstrate the retroperitoneal single-port robotic surgical technique for a kidney tumor.

“There's no question that many patients [undergoing transurethral BPH surgery] can be done as a same-day ambulatory procedure. But you need to look at the criteria as to who you're going to keep and who you're not going to keep,” says Michael A. Palese, MD.

“I think research is a very important tool,” says Padraic O’Malley, MD, MSc, FRCSC.

“I think it's important for urologists and physicians to have an open mind in regard to complementary approaches to the treatment of BPH-related LUTS in men,” says J. Curtis Nickel, MD, FRCSC.

“We definitely don't have a clear standard,” says Shawn Dason, MD, FRCSC.

“These findings are an internal validation that the disparities we're seeing are real,” says Padraic O’Malley, MD, MSc, FRCSC.

“Goal setting for the patient is important,” says Omar El Shahawy, MD, MPH, PhD.

“We call this a ‘disruptive innovation,’” says Leonard S. Marks, MD.

“The most notable finding is that more than half of all adult US women experience urinary incontinence,” says Heidi Wendell Brown, MD, MAS, FACOG.

“There are a few different approaches in perioperative medical chemotherapy or immunotherapy treatment, and it's unclear as to how we should consider all these different approaches,” says Shawn Dason, MD, FRCSC.

“What really needs to be done to show that this works is to look prospectively,” says Amar U. Kishan, MD.

To investigate the severity and prevalence of dermatologic adverse events associated with apalutamide, Mario E. Lacouture, MD, and investigators conducted a study that will help to manage and counsel patients with prostate cancer in the future, especially with the expanded approval of apalutamide in this space.